Zealand: Uneventful Q2 report

BUY, Fair Value DKK113 (+64%)

News published on August Thursday 29, 2013
Share on

Zealand reported this morning Q2 numbers which are not yet very meaningful considering the low level of reported sales by Sanofi in early August. We are still tracking cash burn, although it should not be a worry going forward as Lyxumia’s approval in the US (end of December 2013) and the start of phase III for LixiLan will trigger payments from Sanofi while royalties will go up.

Full report available to subscribers
Please contact marketing@bryangarnier.fr  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities